For example, in non-small cell lung cancer (NSCLC) and other epithelial cancer cell lines, treatment with azacitidine led to the upregulation of PD-L1, as well as genes and pathways involved in innate immunity, adaptive immunity, and immune evasion [32]. Here, CD274 is linked to non-small cell lung carcinoma.